3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1M | -$140M | 0.0% | -10386.5% | -$130M | $101M | $124M |
| 2024 | $200000 | $1.7B | 0.0% | -165724.0% | -$197M | $0 | $153M |
| 2023 | $2M | -$241M | 0.0% | -12178.9% | -$198M | $207M | $278M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$33M | — | — | -$38M | $175M | $162M |
| Dec '25 | $0 | -$33M | — | — | -$30M | $101M | $124M |
| Sep '25 | $0 | -$35M | — | — | -$34M | $100M | $153M |
| Jun '25 | $1M | -$29M | 0.0% | -2106.8% | -$30M | $99M | $187M |
| Mar '25 | $0 | -$43M | — | — | -$36M | $99M | $217M |
| Dec '24 | $100000 | -$48M | 0.0% | -49928.0% | -$44M | $0 | $153M |
| Sep '24 | $0 | -$44M | — | — | -$31M | $0 | $196M |
| Jun '24 | $100000 | $1.9B | 0.0% | -160898.0% | -$59M | $0 | $227M |
| Mar '24 | $0 | -$79M | — | — | -$64M | — | — |
| Dec '23 | $2M | -$94M | 0.0% | -5403.2% | -$60M | $207M | $278M |
| Sep '23 | $119000 | -$52M | 0.0% | -38510.1% | -$55M | — | — |
| Jun '23 | $30000 | -$47M | 0.0% | -137796.7% | — | — | — |
| Mar '23 | — | -$49M | — | — | — | — | — |
How the market has priced INBX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Inhibrx Biosciences, Inc.'s revenue has declined 15.0% per year. These are computed facts, not advice.
As of FY2025, Inhibrx Biosciences, Inc. reported $101M of total debt against $124M of cash; operating income covered interest expense -11.1×.
In FY2025, gross margin was —, operating margin -10386.5%, and net margin -10773.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.